Several preclinical trials have demonstrated that the combination of PD-1/PD-L1 and CTLA-4 inhibitors has a significant synergistic effect in reversing cytotoxic CD8+ T cell exhaustion, attenuating the tumor load and prolonging survival [75]. The gene discussed is CD8A; the disease is neoplasm.